November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

November 20, 2024

New Hope for Hand Function in RA?

Chinese mind-body exercise Yijinjing improved hand function, strength, and flexibility in rheumatoid arthritis patients without exacerbating inflammation

Conexiant

November 20, 2024

4.0 mg/L: The Key to RA Control?

Adalimumab trough levels ≥4.0 mg/L were linked to nearly fourfold higher odds of remission in RA patients, highlighting a potential target for therapeutic drug monitoring.

Conexiant

November 20, 2024

Analysis Identifies New Genetic Loci for Atopic Dermatitis

Conexiant

November 20, 2024

RA's Pre-Disease Phase Only Affects Select Patients

Conexiant

November 20, 2024

Low Citrulline T-Cell Levels Tied to Arthritis Risk

Conexiant

November 20, 2024

EBV: The Virus Behind Multiple Autoimmune Diseases

EBV infects >95% of adults globally, yet only triggers autoimmunity in some - researchers identified several key mechanisms, including autoimmune-promoting EBV strains and genetic variants, that may explain why certain individuals develop diseases like lupus, MS, and rheumatoid arthritis.

Conexiant

November 19, 2024

Triple Therapy Leads Lupus Nephritis Guidelines Update

ACR's 2024 lupus nephritis guidelines signal a shift to a triple therapy approach, moving away from traditional dual immunosuppressive treatment while proposing shorter steroid courses.

Conexiant